Biotest AG’s Promising Phase III Trial for Severe Pneumonia Treatment

Biotest AG ((GB:0N70)) announced an update on their ongoing clinical study.

Biotest AG is conducting a Phase III clinical trial titled A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP). The study aims to evaluate the effectiveness and safety of Trimodulin, an adjunctive treatment to standard care for adults with severe community-acquired pneumonia on invasive mechanical ventilation. This trial is significant as it could offer a new therapeutic option for a serious condition.

The intervention being tested is Trimodulin, a human IgM, IgA, IgG solution administered intravenously. It is designed to enhance the standard of care treatment for patients with severe pneumonia, potentially improving outcomes.

The study is interventional, with a randomized, parallel assignment. Participants are randomly allocated to receive either Trimodulin or a placebo, with both groups receiving standard care. The trial employs quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are blinded to the treatment allocation. The primary purpose is treatment-focused.

The study began on January 11, 2023, and is currently recruiting participants. The primary completion date is yet to be announced, with the last update submitted on July 22, 2025. These dates are crucial as they indicate the study’s progress and potential timeline for results.

This update could positively influence Biotest AG’s stock performance and investor sentiment, as successful trial outcomes may lead to a new product in the market. The pharmaceutical industry is highly competitive, and advancements in severe pneumonia treatment could position Biotest favorably against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.